TScan Therapeutics, Inc.
TCRX
$1.09
$0.043.33%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 2.23% | -18.37% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.23% | -18.37% | |||
| Cost of Revenue | -41.81% | -2.90% | |||
| Gross Profit | 45.60% | 1.29% | |||
| SG&A Expenses | -23.98% | -13.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -38.26% | -5.19% | |||
| Operating Income | 41.01% | 4.14% | |||
| Income Before Tax | 35.66% | 3.36% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 35.66% | 3.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 35.66% | 3.36% | |||
| EBIT | 41.01% | 4.14% | |||
| EBITDA | 41.75% | 4.40% | |||
| EPS Basic | 71.89% | 3.36% | |||
| Normalized Basic EPS | 74.32% | 3.37% | |||
| EPS Diluted | 71.89% | 3.36% | |||
| Normalized Diluted EPS | 74.32% | 3.37% | |||
| Average Basic Shares Outstanding | 128.84% | 0.00% | |||
| Average Diluted Shares Outstanding | 128.84% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||